Novartis and the Bill & Melinda Gates Foundation have partnered on a single-dose, in vivo gene therapy for sickle cell disease (SCD). The foundation has offered to fund the development of the therapy. Read the full article HERE
Novartis and Gates Foundation Team Up To Deliver Affordable Sickle Cell Gene Therapy
April 21, 2021
